BARCELONA, Spain & MONTPELLIER, France--(BUSINESS WIRE)--SeqOne, provider of new generation genomic analysis solutions for personalized medicine, is announcing at the ESMO GYNAE conference a new HRD ...

The filing comes as recent upgrades to NCCN guidelines expand the role of testing in the treatment of ovarian cancer. Myriad Genetics this week submitted the first part of its application to the FDA ...

Tesaro has made a deal with Myriad Genetics to use Myriad's homologous recombination deficiency (HRD) test to look for tumor types that may respond to its poly-ADP ribose polymerase (PARP) inhibitor, ...

Molecular diagnostics company Myriad Genetics signed an agreement with PharmaMar, a company that specializes in developing marine-derived drugs, under which Myriad will conduct homologous ...

New assay brings validated HRD technology from Myriad Genetics (MYGN) to the Illumina TruSight™ Oncology 500, a single, comprehensive pan-cancer test to identify key variants critical for cancer ...

CHICAGO, May 31, 2020 (GLOBE NEWSWIRE) -- Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, announced the launch of ...

The ability of the Geneva homologous recombination deficiency (HRD) test to predict progression-free survival (PFS) in patients with high-grade ovarian cancer treated with poly (ADP-ribose) polymerase ...

Highly Sensitive Circulating Tumor DNA Assay Aids Clinical Management of Radiographically Occult Isolated Peritoneal Metastases in Patients With GI Cancer The efficiency of the Myriad Homologous ...

Next-generation-sequencing-based homologous recombination deficiency (HRD) assay based on QIAGEN’s QIAseq xHYB technology, QIAGEN Digital Insight solutions, and Myriad’s proprietary, FDA-approved ...

QIAGEN N.V. QGEN, together with Myriad Genetics MYGN, will develop a globally distributable kit-based test for analyzing Homologous Recombination Deficiency (HRD) status. The endeavor expands upon the ...

Myriad Genetics, Inc. MYGN today announced that it has signed an agreement with PharmaMar, a leader in the development of marine-derived drugs. Under the terms of the agreement, Myriad will conduct ...